Like most breast cancer signatures, BRmet50 and PMID18271932Sig33 are derived from datasets in which ER-positive (ER+) tumors predominant and perform well in the prediction of prognosis in ER+ tumors but poorly in ER- tumors (Table 4). This evidence concerns the gene ESR1 and breast cancer.